The News Review:

- Managing Implant Complications Flapless Surgery and much more’
- Indian il Corporation donates Rs. 1 crore to Sankara Nethralaya
- Teva lifts outlook faces Wyeth reflux-patent claim
- Delayed Adoption of New Treatments in Developing World Costs Lives
- TomoTherapy(R) Cancer Treatment Technology Debuts In Switzerland

Managing Implant Complications Flapless Surgery and much more’
sseoNews – Dec 25, 2007
Sclar authored a hallmark multilanguage textbook entitled; Soft Tissue and Esthetic Considerations in Implant Therapy (Quintessence2003). A dedicated professional Dr. Sclar serves as an editor for the dental implant surgery section of the Journal of ral and Maxillofacial Surgery and is the Director of Clinical Research and Post Graduate Dental Implant Surgery in the department of ral and Maxillofacial Surgery at Nova Southeastern University School of Dentistry. In February 2008 Dr. Sclar will be hosting a Comprehensive Implant Surgery Training Conference in Florida.

Indian il Corporation donates Rs. 1 crore to Sankara Nethralaya
Hindu – Dec 25, 2007
“We have been carrying out research work for the last 20 years and have gained recognition nationally and internationally. The culmination of this project would help humanity to a larger extent. ”Till date VRF mobilised Rs. 19 crore from well known corporate houses and individuals to undertake clinical research. It sought the help of corporate houses and philanthropists to support their cause. Badrinath officials of the U.

Teva lifts outlook faces Wyeth reflux-patent claim
marketwatch.com – Dec 25, 2007
Wyeth said that the court said Teva had raised enough questions about the patent’s validity to prevent issuance of an injunction. But the court also said that at trial Teva would have to prove “by clear and convincing evidence that the patent is not valid. ” The Protonix patent will expire in July 2010 “but Wyeth’s marketing exclusivity may be extended until January 2011 as a result of clinical research undertaken by the company regarding the pediatric use of the product” Wyeth said. Teva said that the two sides have begun discussing a settlement and that they’ve entered a standstill agreement under which Teva won’t ship more of the product for 30 days. Regarding the second approvable letter Wyeth received on its osteoporosis drug the FDA said several questions remained “regarding issues that had been previously identified during the review process and that were not fully resolved” by Wyeth’s response to the first approvable letter which was issued in April the drugmaker said. The FDA wants “further analyses and discussion concerning the incidence of stroke and venous thrombotic events” Wyeth said. “The agency also identified certain issues concerning data collection and reporting and requested additional source documents.

Delayed Adoption of New Treatments in Developing World Costs Lives
Kansas City infoZine – Dec 25, 2007
investments in global health. “Instead planners often assume that clinical research findings can be immediately translated into public health impact simply by issuing ‘one-size-fits-all’ clinical guidelines or best practices without engaging in systematic study of how health outcomes vary across community settings” according to Glass. He calls on the research community to adopt three goals to improve implementation in the developing world. First scientists should work to advance theoretical models and new analytic methods that apply to resource-poor settings. Second they should train a generation of researchers in interdisciplinary systems-oriented approaches that will allow them to more effectively bridge the implementation gap. Finally researchers should collaborate more closely with developing country governments non-governmental organizations and local communities.

TomoTherapy(R) Cancer Treatment Technology Debuts In Switzerland
Medical News Today – Medical News Today (press release) – Dec 25, 2007
About the CHUV CHUV is one of the 5 major university hospitals in Switzerland. It provides from primary to tertiary care in all domains of medicine and one of its major focuses is cancer. Many doctors and scientists are involved in basic translational and clinical research in cancer medicine which contributes to its international visibility. A number of clinicians are currently involved in national and international cooperative cancer research groups including SAKK ERTC and hold officer’s positions or have a leading role as principal investigators of international trials. The department of Radiation ncology has an active role and has contributed to a number of major international studies in various fields of oncology and has a leading position in Switzerland About TomoTherapy Incorporated TomoTherapy Incorporated has developed manufactures and sells the TomoTherapy® Hi-Art® treatment system an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company completed its initial public offering in May 2007 and its stock is traded on the NASDAQ Global Market under the symbol TTPY.